Tizanidine Tablet
Product Images NDC 76420-229

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Tizanidine (NDC 76420-229). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Asclemed Usa, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Image Description (Container1)

This is the packaging information for Tizanidine Tablets. The tablets are available in 2mg and come in three different packages: 30, 60 and 90 tablets. The manufacturer of the tablets is Dr. Reddy's Laboratories Limited. The tablets are prescribed as they come under RX drugs. The packaging inserts caution to keep the tablets away from children and store them at a temperature between 20-25C (USP Controlled Room Temp). The lot and batch numbers are mentioned on the package along with their expiry dates.*

FDA Label Image

Image Description (Container2)

The text is a collection of labels and packaging information for Tizanidine Tablets, USP 4mg, a prescription drug manufactured by Dr. Reddy's Laboratories Limited. It includes the NDC numbers, product quantity, batch numbers, drug status, and cautionary statements. The tablets are packaged in 30, 60, and 90 count bottles by 9 Enovachem with varying lot numbers and batch numbers. The tablets are described as white and off-white with pill numbers printed on them. Storage and safety instructions are also included.*

FDA Label Image

Image Description (Fig1)

This is a chart that presents plasma Tzanidine concentration in ng/mL at different hours from dosing based on various conditions, such as taking 2x 4mg Tzanidine tablets with or without food, or taking 2x 4mg Tzanidine capsules with or without food. The name "Mamar RAS" appears to be a reference to a specific study or experiment.*

FDA Label Image

Image Description (Fig2)

The text presents a graph or chart showing the improvement in Ashworth score after taking 16 mg of tizanidine compared to placebo, over a certain number of hours post-dose. No further information or context is available.*

FDA Label Image

Image Description (Fig3)

The text describes the improvement in the Ashworth Score after administering a medication called "zanidine" with a mean dose of 28.6 mg. However, it does not provide any specific details regarding the results of the study or the condition being treated. The timeline mentioned is the study's third week, end of maintenance endpoint, and last observation carried forward at study week 7.*

FDA Label Image

Image Description (Structure)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.